APOBEC3G expression correlates with T-cell infiltration and improved clinical outcomes in high-grade serous ovarian carcinoma

Clinical Cancer Research

Volumn 22, Issue 18, 2016, Pages 4746-4755

  Leonard, Brandon ^a,b   Starrett, Gabriel J ^a,b   Maurer, Matthew J ^c   Oberg, Ann L ^c   Van Bockstal, Mieke ^d   Van Dorpe, Jo ^d   De Wever, Olivier ^d   Helleman, Jozien ^e   Sieuwerts, Anieta M ^e   Berns, Els M J J ^e   Martens, John W M ^e   Anderson, Brett D ^a,b   Brown, William L ^a,b   Kalli, Kimberly R ^f   Kaufmann, Scott H ^c,g   Harris, Reuben S ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MAYO CLINIC   (United States)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e ERASMUS MC CANCER INSTITUTE   (Netherlands)

^f MAYO CLINIC CANCER CENTER   (United States)

^g MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CD4 ANTIGEN; CD8ALPHA ANTIGEN; APOBEC3G PROTEIN, HUMAN; TUMOR MARKER;

APOBEC3B GENE; APOBEC3G GENE; ARTICLE; CANCER PROGNOSIS; CD3D GENE; CD4 GENE; CD8A GENE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GZMB GENE; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRF1 GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RNF128 GENE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; UPREGULATION; CANCER GRADING; COHORT ANALYSIS; CYSTADENOCARCINOMA; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOCYTE ACTIVATION; METABOLISM; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR ASSOCIATED LEUKOCYTE;

APOBEC-3G DEAMINASE; BIOMARKERS, TUMOR; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM GRADING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84988844163     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2910     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004; 23:41-4.
3. Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, et al. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunol Immunother 2015;64:1495-504.
4. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 2012;18:3281-92.
5. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
6. Sato E, Olson SH, Ahn J, Bundy B, NishikawaH,Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
7. Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, et al. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3≥ T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS ONE 2013;8:e80063.
8. Harris RS, Petersen-Mahrt SK, Neuberger MS. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 2002;10:1247-53.
9. Refsland EW, Harris RS. The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol 2013;371:1-27.
10. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 2007;76:1-22.
11. Harris RS, Hultquist JF, Evans DT. The restriction factors of human immunodeficiency virus. J Biol Chem 2012;287:40875-83.
12. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 2010;38:4274-84.
13. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 2011;85:11220-34.
14. Refsland EW, Hultquist JF, Harris RS. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T-cell line CEM2n. PLoS Pathog 2012;8:e1002800.
15. Koning FA, Newman ENC, Kim E-Y, Kunstman KJ, Wolinsky SM, Malim MH. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 2009;83:9474-85.
16. Liddament MT, Brown WL, Schumacher AJ, Harris RS. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 2004;14:1385-91.
17. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013;494:366-70.
18. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol 2010;17:222-9.
19. Thielen BK, McNevin JP, McElrath MJ, Hunt BVS, Klein KC, Lingappa JR. Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem 2010;285:27753-66.
20. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-8.
21. Leonard B, McCann JL, Starrett GJ, Kosyakovsky L, Luengas EM, Molan AM, et al. The PKC/NF-kB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res 2015;75:4538-47.
22. Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, et al. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio 2014;5:e02234-14.
23. Robbiani DF, Nussenzweig MC. Chromosome translocation, B-cell lymphoma, and activation-induced cytidine deaminase. Annu Rev Pathol 2013;8:79-103.
24. Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, et al. APOBEC3B upregulation and genomicmutation patterns in serous ovarian carcinoma. Cancer Res 2013;73:7222-31.
25. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013;45:977-83.
26. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBECcytidine deaminase mutagenesis pattern iswidespread in human cancers. Nat Genet 2013;45:970-6.
27. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.
28. Burns MB, Leonard B, Harris RS.APOBEC3B: pathological consequences of an innate immune DNA mutator. Biomed J 2015;38:102-10.
29. Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov 2015;5:704-12.
30. Roberts SA, Gordenin DA. Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer 2014;14:786-800.
31. Sieuwerts AM, Willis S, Burns MB, Look MP, Meijer-Van Gelder ME, Schlicker A, et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer 2014; 5:405-13.
32. Cescon DW, Haibe-Kains B, Mak TW. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci 2015;112: 2841-6.
33. PeriyasamyM, Patel H, Lai C-F, Nguyen VTM, Nevedomskaya E, Harrod A, et al. APOBEC3B-mediated cytidine deamination is required for estrogen receptor action in breast cancer. Cell Rep 2015;13:108-21.
34. Tsuboi M, Yamane A, Horiguchi J, Yokobori T, Kawabata-Iwakawa R, Yoshiyama S, et al. APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers. Breast Cancer. 2015; Oct [Epub ahead of print]
35. Xu L, Chang Y, An H, Zhu Y, Yang Y, Xu J. High APOBEC3B expression is a predictor of recurrence in patients with low-risk clear cell renal cell carcinoma. Urol Oncol 2015;33:340.
36. Zhang J, Wei W, Jin H-C, Ying R-C, Zhu A-K, Zhang F-J. The roles of APOBEC3B in gastric cancer. Int J Clin Exp Pathol 2015;8:5089-96.
37. Ding Q, Chang C-J, Xie X, Xia W, Yang J-Y, Wang S-C, et al. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest 2011; 121:4526-36.
38. Caval V, Suspéne R, Shapira M, Vartanian J-P, Wain-Hobson S. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 30UTR enhances chromosomal DNA damage. Nat Commun 2014;5:5129.
39. Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet 2014;46:487-91.
40. Chan K, Roberts SA, Klimczak LJ, Sterling JF, Saini N, Malc EP, et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet 2015;47:1067-72.
41. Verschuere S, Bracke KR, Demoor T, Plantinga M, Verbrugghe P, Ferdinande L, et al. Cigarette smoking alters epithelial apoptosis and immune composition in murine GALT. Lab Invest 2011; 91:1056-67.
42. Gyorffy B, Lànczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovariancancer using microarray data from 1287 patients. Endocr Relat Cancer 2012;19:197-208.
43. Schuyer M, van der Burg ME, Henzen-Logmans SC, Fieret JH, Klijn JG, Look MP, et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 2001;85:1359-67.
44. Wichkham H. ggplot2: elegant graphics for data analysis. New York: Springer Publishing Company; 2016.
45. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415-28.
46. Sabek O, Dorak MT, Kotb M, Gaber AO, Gaber L. Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathologic evaluation. Transplantation 2002;74:701-7.
47. Zheng Y, Zha Y, Gajewski TF. Molecular regulation of T-cell anergy. EMBO Rep 2008;9:50-5.
48. Schwartz RH. T cell anergy. Annu Rev Immunol 2003;21:305-34.
49. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
50. Sohn I, Jung WY, Sung CO. Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer. Gynecol Oncol 2012;126:103-8.